Dogwood Therapeutics, Inc. (DWTX): Operating Cash Flow
-$15.62M
Year ended 2025-12-31
-$15.11M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$15.62M | n/m | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | -$8.79M | n/m | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | -$4.87M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$11.47M | n/m | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | -$15.69M | n/m | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | -$3.90M | n/a | 2022-03-18, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | -$15.62M | n/m |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | -$25.25M | n/m |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | -$39.88M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.50M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $10.52M | +986.1% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | -$45.79M | n/m |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | -$28.55M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$12.44M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
Compare DWTX, VTVT, STTK, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗